Loading…
Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 negative allosteric modulator (NAM) for chronic spontaneous urticaria and other mast cell diseases; and TSHR Program, an oral small molecule TSHR NAM for graves' disease and thyroid eye disease. In addition, it focuses on other therapeutic areas, including neurology, women's health, cardiovascular disease, and respiratory disease. It has global collaboration and license agreement with Novo Nordisk to discover, develop and commercialize multiple potential oral small molecule therapies for metabolic-related diseases based on certain specified molecular targets. The company was formerly known as GPCR NewCo, Inc. and changed its name to Septerna Inc. in June 2021. Septerna, Inc. was incorporated in 2019 and is headquartered in South San Francisco, California.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $46M | $-79M | $-49M | $110M | -12.8% | 4174.5% | -31.9% |
| 2024 | $1M | $-79M | $-72M | $-70M | -17.1% | 611.9% | -1817.7% |
| 2023 | $0M | $-45M | $4M | $-42M | -10.9% | - | -115.1% |
| 2022 | $0M | $-27M | $-28M | $-25M | 62.6% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total Revenue | 0 | 0.15 | 1.08 | 45.95 |
| Operating Revenue | 0 | 0.15 | 1.08 | 45.95 |
| Operating Expense | 27.97 | 45.70 | 81.90 | 126.75 |
| Research And Development | 22.04 | 35.98 | 65.34 | 97.58 |
| Selling General And Administration | 5.92 | 9.72 | 16.56 | 29.16 |
| Total Expenses | 27.97 | 45.70 | 81.90 | 126.75 |
| Operating Income | -27.97 | -45.55 | -80.82 | -80.80 |
| Total Operating Income As Reported | -27.97 | 2.08 | -80.82 | -68.30 |
| EBITDA | -27.39 | -44.70 | -79.42 | -79.19 |
| Normalized EBITDA | -27.39 | -92.33 | -79.42 | -91.69 |
| EBIT | -27.97 | -45.55 | -80.82 | -80.80 |
| Interest Income | 0.29 | 2.79 | 8.62 | 19.53 |
| Net Interest Income | 0.29 | 2.79 | 8.62 | 19.53 |
| Other Non Operating Income Expenses | - | 0.01 | -0.09 | -0.10 |
| Other Income Expense | - | 47.64 | -0.09 | 12.40 |
| Interest Income Non Operating | 0.29 | 2.79 | 8.62 | 19.53 |
| Net Non Operating Interest Income Expense | 0.29 | 2.79 | 8.62 | 19.53 |
| Pretax Income | -27.68 | 4.87 | -72.30 | -48.87 |
| Tax Provision | 0 | 0.69 | -0.50 | 0.01 |
| Tax Rate For Calcs | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | 0 | 6.76 | 0 | 0 |
| Net Income Continuous Operations | -27.68 | 4.18 | -71.80 | -48.88 |
| Net Income From Continuing And Discontinued Operation | -27.68 | 4.18 | -71.80 | -48.88 |
| Net Income From Continuing Operation Net Minority Interest | -27.68 | 4.18 | -71.80 | -48.88 |
| Net Income | -27.68 | 4.18 | -71.80 | -48.88 |
| Net Income Common Stockholders | -27.68 | 0.57 | -71.80 | -48.88 |
| Net Income Including Noncontrolling Interests | -27.68 | 4.18 | -71.80 | -48.88 |
| Normalized Income | -27.68 | -36.68 | -71.80 | -61.38 |
| Diluted NI Availto Com Stockholders | -27.68 | 0.63 | -71.80 | -48.88 |
| Basic Average Shares | 19.50 | 19.50 | 9.89 | - |
| Diluted Average Shares | 19.50 | 19.50 | 9.89 | - |
| Reconciled Depreciation | 0.58 | 0.85 | 1.40 | 1.60 |
| Total Unusual Items | 0 | 47.62 | 0 | 12.50 |
| Total Unusual Items Excluding Goodwill | 0 | 47.62 | 0 | 12.50 |
| Special Income Charges | 0 | 47.62 | 0 | 12.50 |
| General And Administrative Expense | 5.92 | 9.72 | 16.56 | 29.16 |
| Other Gand A | 5.92 | 9.72 | 16.56 | 29.16 |
| Gain On Sale Of Ppe | 0 | 47.62 | 0 | 12.50 |
| Otherunder Preferred Stock Dividend | 0 | 3.61 | 0 | - |
| Average Dilution Earnings | - | 0.06 | - | - |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Septerna, Inc.this co. | SEPN | $1.4B | -28.93 | 3.70 | -12.8% | -16.63 |
| Monte Rosa Therapeutics, Inc. | GLUE | $1.5B | -37.97 | 6.29 | -16.6% | -30.01 |
| Aveanna Healthcare Holdings Inc. | AVAH | $1.4B | 6.42 | 7.40 | 115.3% | 10.26 |
| Maze Therapeutics, Inc. | MAZE | $1.4B | -10.72 | 3.96 | -36.9% | -8.82 |
| Healthcare Services Group, Inc. | HCSG | $1.4B |
| 23.77 |
| 2.75 |
| 11.6% |
| 14.94 |
| AtriCure, Inc. | ATRC | $1.4B | -120.63 | 2.81 | -2.3% | 79.22 |
| Precigen, Inc. | PGEN | $1.4B | -5.49 | 65.81 | -1198.6% | -5.93 |
| Integra LifeSciences Holdings Corporation | IART | $1.4B | -2.65 | 1.31 | -49.5% | -9.72 |
| MapLight Therapeutics, Inc. | MPLT | $1.4B | - | 2.98 | -35.2% | - |
| Peer Median | - | -5.49 | 3.47 | -25.9% | -5.93 | |